Unigestion Holding SA Has $8.42 Million Stock Position in McKesson Co. (NYSE:MCK)

Unigestion Holding SA lessened its position in McKesson Co. (NYSE:MCK) by 32.1% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 14,773 shares of the company’s stock after selling 6,977 shares during the period. Unigestion Holding SA’s holdings in McKesson were worth $8,419,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Millstone Evans Group LLC bought a new stake in McKesson during the 4th quarter valued at $28,000. Synergy Asset Management LLC acquired a new stake in shares of McKesson in the 4th quarter worth about $32,000. Crews Bank & Trust bought a new position in McKesson in the 4th quarter valued at about $33,000. Atala Financial Inc acquired a new position in McKesson during the 4th quarter valued at about $34,000. Finally, Graney & King LLC acquired a new position in McKesson during the 4th quarter valued at about $38,000. Institutional investors own 85.07% of the company’s stock.

Insider Transactions at McKesson

In related news, EVP Leann B. Smith sold 188 shares of McKesson stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $609.59, for a total value of $114,602.92. Following the transaction, the executive vice president now owns 1,051 shares in the company, valued at $640,679.09. This trade represents a 15.17 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Brian S. Tyler sold 8,961 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $600.66, for a total transaction of $5,382,514.26. Following the sale, the chief executive officer now owns 69,625 shares of the company’s stock, valued at approximately $41,820,952.50. The trade was a 11.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,110 shares of company stock valued at $10,855,706. Insiders own 0.11% of the company’s stock.

McKesson Price Performance

Shares of MCK opened at $682.41 on Friday. The firm has a market cap of $85.52 billion, a PE ratio of 31.25, a PEG ratio of 1.29 and a beta of 0.49. McKesson Co. has a 1 year low of $464.42 and a 1 year high of $728.32. The stock’s fifty day moving average price is $633.37 and its two-hundred day moving average price is $585.40.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. Sell-side analysts anticipate that McKesson Co. will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 0.42%. The ex-dividend date was Monday, March 3rd. McKesson’s dividend payout ratio (DPR) is currently 13.00%.

Analyst Upgrades and Downgrades

MCK has been the topic of a number of recent research reports. Evercore ISI raised their target price on McKesson from $650.00 to $675.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. StockNews.com downgraded shares of McKesson from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Citigroup lowered their target price on shares of McKesson from $713.00 to $677.00 and set a “buy” rating for the company in a report on Friday, January 10th. Wells Fargo & Company boosted their price target on shares of McKesson from $641.00 to $691.00 and gave the stock an “equal weight” rating in a report on Friday, March 14th. Finally, Bank of America decreased their price objective on shares of McKesson from $680.00 to $650.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, McKesson has a consensus rating of “Moderate Buy” and a consensus price target of $661.00.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.